__timestamp | Catalent, Inc. | Merus N.V. |
---|---|---|
Wednesday, January 1, 2014 | 334800000 | 3852327 |
Thursday, January 1, 2015 | 337300000 | 839656 |
Friday, January 1, 2016 | 358100000 | 4478145 |
Sunday, January 1, 2017 | 402600000 | 16432324 |
Monday, January 1, 2018 | 462600000 | 11890871 |
Tuesday, January 1, 2019 | 512000000 | 34110000 |
Wednesday, January 1, 2020 | 577900000 | 35781000 |
Friday, January 1, 2021 | 687000000 | 40896000 |
Saturday, January 1, 2022 | 844000000 | 52200000 |
Sunday, January 1, 2023 | 831000000 | 59836000 |
Monday, January 1, 2024 | 935000000 |
Data in motion
In the ever-evolving landscape of corporate finance, understanding Selling, General, and Administrative (SG&A) expenses is crucial for effective cost management. Catalent, Inc. and Merus N.V. offer a compelling narrative of contrasting financial strategies over the past decade.
From 2014 to 2023, Catalent, Inc. has seen a steady increase in SG&A expenses, peaking at approximately 935 million in 2024, reflecting a growth of nearly 180% from 2014. This upward trend suggests a strategic investment in operational expansion and market penetration. In contrast, Merus N.V. has experienced a more volatile trajectory, with expenses rising from under 1 million in 2015 to nearly 60 million in 2023, indicating a significant scale-up in operations.
While Catalent's consistent growth underscores its robust market strategy, Merus's fluctuating expenses highlight the challenges and opportunities in scaling operations. Missing data for 2024 suggests ongoing financial adjustments.
Comparing SG&A Expenses: Pfizer Inc. vs Catalent, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Catalent, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Catalent, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Catalent, Inc. Trends and Insights
Catalent, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Catalent, Inc. and BioCryst Pharmaceuticals, Inc.
Opthea Limited and Merus N.V.: SG&A Spending Patterns Compared
Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.
Merus N.V. vs Novavax, Inc.: SG&A Expense Trends